Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
2.250
+0.150 (7.14%)
At close: Dec 20, 2024, 4:00 PM
2.247
-0.003 (-0.13%)
After-hours: Dec 20, 2024, 6:44 PM EST
Cocrystal Pharma Employees
Cocrystal Pharma had 12 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,558,500
Market Cap
22.89M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Allurion Technologies | 504 |
Athira Pharma | 67 |
Equillium | 44 |
VSee Health | 40 |
Pulmatrix | 22 |
NeurAxis | 19 |
GeoVax Labs | 17 |
NanoViricides | 7 |
COCP News
- 4 months ago - Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences - GlobeNewsWire
- 4 months ago - CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event - Accesswire
- 7 months ago - Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 8 months ago - Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza - GlobeNewsWire
- 9 months ago - Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 9 months ago - Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A - GlobeNewsWire
- 10 months ago - Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap - Accesswire
- 1 year ago - Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A - GlobeNewsWire